Data on Immunology Effects of Provectus Biopharmaceuticals PV-10 in Colon Cancer Presented at 11th Annual ASC Meeting
February 03 2016 - 6:00AM
Business Wire
Result Consistent with Immunologic Cell
Death Caused by PV-10
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,
www.pvct.com), a clinical-stage oncology and dermatology
biopharmaceutical company ("Provectus" or “the Company”), today
announced data discussing the immunologic effects of PV-10 on colon
cancer cells were presented yesterday at the 11th Annual Academic
Surgical Congress in Jacksonville, Florida.
The abstract, titled “PV-10 Induces Potent Immunogenic Apoptosis
in Colon Cancer Cells,” was presented by N. M. Kunda of the
University of Illinois at Chicago, Division of Surgical Oncology,
Department of Surgery, College of Medicine, Chicago, IL, USA. The
research team is led by Dr. A.V. Maker, and co-authors in addition
to Drs. Kunda and Maker are: J. Qin, G. Qiao also of UIC, Division
of Surgical Oncology, Department of Surgery. The team of authors
also includes B. Prabhakar of the University of Illinois at
Chicago, Department of Microbiology & Immunology, College of
Medicine, Chicago, IL, USA. Dr. Maker belongs to both
Departments.
In the presentation, Dr. Kunda noted that in vitro testing of
PV-10 on colon cancer (murine CT-26 cells) showed cytotoxicity
consistent with immunogenic apoptosis. Further, he stated that the
researchers observed cell arrest, apoptosis, autophagy and
endoplasmic reticulum (ER) stress. He concluded that these results
are consistent with immunologic cell death caused by PV-10.
Dr. Eric Wachter, CTO of Provectus, said, “The work reported in
Dr. Kunda’s presentation further expands our understanding of the
mechanism of action of PV-10 as an ablative immunotherapy for solid
tumors, and parallels immunologic signaling noted upon ablation of
melanoma with PV-10.”
About the Academic Surgical Congress
The Academic Surgical Congress is organized by the Association
for Academic Surgery (AAS) and the Society of University Surgeons
(SUS). The purpose of the AAS is to stimulate young surgeons and
surgical scientists to pursue careers in academic surgery and
support them in establishing themselves as investigators and
educators; to provide a forum for senior surgical residents,
fellows and junior faculty members to present papers on subjects of
clinical, laboratory or educational research; and to facilitate the
development of young surgeons and surgical scientists as
investigators and educators. Its additional mission is to inspire
and develop young academic surgeons. The SUS exists to advance the
art and science of surgery by (1) the encouragement of its members
to pursue original investigations both in the clinic and in the
laboratory; (2) the development of methods of graduate teaching of
surgery with particular reference to the resident system; (3) free
and informal interchange of ideas pertaining to the above
subjects.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing
oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into
solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has
completed Phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company's other
clinical trials can be found at the NIH
registry, www.clinicaltrials.gov. For additional information
about Provectus, please visit the Company's website
at www.pvct.com or contact Porter, LeVay & Rose,
Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2014) and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with the
fully enrolled phase 3 trial of PV-10 to treat locally advanced
cutaneous melanoma and the costs associated with such a trial if it
is necessary to complete (versus interim data alone);
- our determination whether to license
PV-10, our investigational drug product for melanoma and other
solid tumors such as cancers of the liver, if such licensure is
appropriate considering the timing and structure of such a license,
or to commercialize PV-10 on our own to treat melanoma and other
solid tumors such as cancers of the liver;
- our ability to license PH-10, our
investigational drug product for dermatology, PH-10, on the basis
of our phase 2 atopic dermatitis and psoriasis results, which are
in the process of being further developed in conjunction with
mechanism of action studies; and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160203005301/en/
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper,
866-594-5999 #30CFO, COOorPorter, LeVay & Rose, Inc.Marlon
Nurse, 212-564-4700DM, SVP – Investor RelationsorAllison +
PartnersTodd Aydelotte, 646-428-0644Managing Director –Media
Relations
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Sep 2023 to Sep 2024